ClinicalTrials.gg
RecruitingNCT06921980Updated Nov 4, 2026

Brain Function and Psychological Changes Related to Cell Therapy for Autoimmune Hemolytic Anemia

An observational study in CAR T-cell Therapy, Autoimmune Hemolytic Anemia and Brain Function, sponsored by Institute of Hematology & Blood Diseases Hospital, China. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Institute of Hematology & Blood Diseases Hospital, China · Observational

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 8 months later.
Updated Nov 4, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
20
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 15 studies in Anemia, Hemolytic, Autoimmune by Institute of Hematology & Blood Diseases Hospital, China — 8 open to participants now, 12 under way, none of them phase 3. Anemia, Hemolytic, Autoimmune · Institute of Hematology & Blood Diseases Hospital, China.

Started
2025
with 2 others
Observational
4 of 15
4 open now
Primary completion
2027-12
later than 6 of 11 live
Registered
10th of 15
by date

Among the 15 studies in Anemia, Hemolytic, Autoimmune by Institute of Hematology & Blood Diseases Hospital, China, this one is one of 3 that started in 2025, is one of 4 observational ones, reaches primary completion later than 6 of the 11 other live ones, and was the 10th registered.

Anemia, Hemolytic, Autoimmune

103 studies on the registry are indexed under Anemia, Hemolytic, Autoimmune; 39 are open to participants now.

Browse Anemia, Hemolytic, Autoimmune studies →

Open to participants now

8 of the 15 studies in Anemia, Hemolytic, Autoimmune by Institute of Hematology & Blood Diseases Hospital, China are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 24 Anemia, Hemolytic, Autoimmune studies recruiting now, 12 (50%) set no upper age limit and 10 (42%) stop at 75 or younger; 5 take children under 18; none take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Anemia, Hemolytic, Autoimmune by Institute of Hematology & Blood Diseases Hospital, China, or all of them as a file.
02

Study summary

Cell therapy is an innovative treatment with significant efficacy in hematologic and certain autoimmune diseases. Although it offers potential benefits for autoimmune hemolytic anemia (AIHA), it may result in cognitive and other potential impairments, which can adversely affect patients' cognition and behavior.

Brain function and psychological assessment are essential for the early detection of potential impairments, allowing timely interventions to prevent complications and ensure patient safety. This study aims to comprehensively evaluate the physical and psychological impacts of cell therapy on AIHA patients to develop safer and more effective treatment strategies that enhance their quality of life.

03

Conditions studied

  • CAR T-cell Therapy
  • Autoimmune Hemolytic Anemia
  • Brain Function
  • Psychological Well-Being
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with relapsed/refractory AIHA who will receive cell therapy, such as CAR T-cell therapy, from 2025 to 2026.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of AIHA
  • Subjects will receive cell therapy such as CAR T-cell therapy
  • Male or female, aged 18-65 years
  • Willing and able to comply with the requirements for this study and written

Exclusion criteria

Exclusion Criteria:

  • History of psychiatric illness
  • History of severe brain disease
  • Subjects that the investigator believes have other reasons that make them unsuitable for inclusion in this study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
20 participants (estimated)
Patient registry
No

Groups and cohorts

  • Experimental

    Brain function and psychological changes in AIHA patients will be monitored throughout cell therapy.

    Other: Brain function and psychological assessment

Interventions

  • OtherBrain function and psychological assessment

    Patients will be assessed before cell therapy and on Days 1, 4, 7, 10, 14, 21, and 28 after treatment.

06

What researchers measure

Primary outcomes

  1. Concentration changes in oxygenated hemoglobin (HbO) and de-oxygenated hemoglobin (HbR)

    Functional Near Infrared Spectroscopy (fNIRS) is a non-invasive brain imaging modality, that can be used to measure HbO and HbR concentrations.

    Time frame: Patients will be assessed before cell therapy and on Days 1, 4, 7, 10, 14, 21, and 28 after treatment.

  2. Psychological change

    The Big Five Inventory-2(BFI-2) is used to measure the five broad dimensions of personality: openness, conscientiousness, extraversion, agreeableness, neuroticism. Higher scores indicate a stronger presence of that personality trait.

    Time frame: Patients will be assessed before cell therapy and on Days 1, 4, 7, 10, 14, 21, and 28 after treatment.

  3. Anxiety symptoms

    Hamilton anxiety scale(HAMA) is used to examine anxiety in AIHA patients, with higher total scores indicate more severe anxiety symptoms. The total score range is 0-56.

    Time frame: Patients will be assessed before cell therapy and on Days 1, 4, 7, 10, 14, 21, and 28 after treatment.

  4. Depression symptoms

    Hamilton depression scale(HAMD) is used to examine depression in AIHA patients, with higher total scores indicate more severe depression symptoms. The total score range is 0-52.

    Time frame: Patients will be assessed before cell therapy and on Days 1, 4, 7, 10, 14, 21, and 28 after treatment.

Secondary outcomes

  1. Sleep quality

    The Pittsburgh Sleep Quality Index (PSQI) was used to assess sleep quality, with a higher global score indicating poorer sleep quality. The global score range is 0-21.

    Time frame: Patients will be assessed before cell therapy and on Days 1, 4, 7, 10, 14, 21, and 28 after treatment.

  2. Physical fatigue

    It measured by the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Scale. The total possible score is 0-52 points, with higher scores indicating less fatigue.

    Time frame: Patients will be assessed before cell therapy and on Days 1, 4, 7, 10, 14, 21, and 28 after treatment.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Feb 2025 (actual). Primary completion is estimated for Dec 2027, 34 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: primary completion Dec 2026 → Dec 2027 and completion Dec 2026 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2025
First posted
Apr 10, 2025
StartActual
Feb 25, 2025
Primary completionEst.
Dec 31, 2027was Dec 2026
CompletionEst.
Dec 31, 2028was Dec 2026
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 31, 2026→Dec 31, 2027
Nov 4, 2026
Study completion
Dec 31, 2026→Dec 31, 2028
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Primary completion Dec 31, 2026→Dec 31, 2027
    Study completion Dec 31, 2026→Dec 31, 2028
    + 3 other changes: verification date, responsible party and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06921980
Collaborators
Tianjin University
Responsible party
Kuang Zhexiang (Head nurse of Regenerative Medical Center, Institute of Hematology & Blood Diseases Hospital, China) — Principal investigator
First posted
Apr 10, 2025
Start date
Feb 25, 2025
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Nov 4, 2026

Study contacts

Zhexiang Kuang, MSN
Contact
kuangzhexiang@ihcams.ac.cn
13920361752
Xiao Yu, Undergraduate
Contact
yuxiao@ihcams.ac.cn
18722218448

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion